ClinicalTrials.gg
CompletedNCT01363440VISTA DMEUpdated May 30, 2016Results posted

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

A Phase 3 interventional study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) and Macular Laser Photocoagulation in Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Completed at 51 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-30.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
466
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing aflibercept in Diabetic Retinopathy — 2 open to participants now, 4 under way, none of them phase 3. aflibercept · Diabetic Retinopathy.

Enrollment
Largest of 21
466 · median 38
Started
2011
the only one that year
Phase 3
3 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
2 of 21
Regeneron Pharmaceuticals

Among the 21 studies testing aflibercept in Diabetic Retinopathy, this one has the largest enrollment, is the only one that started in 2011, is one of 3 in phase 3, and was the 1st registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 21 studies testing aflibercept in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing aflibercept in Diabetic Retinopathy, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in patients with diabetic macular edema (DME) with central involvement.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
  • Diabetic Retinopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following is an abbreviated list of inclusion criteria:

  • Adults ≥ 18 years with type 1 or 2 diabetes mellitus
  • Decrease in vision determined to be primarily the result of DME in the study eye
  • BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye

Exclusion criteria

Exclusion Criteria:

The following is an abbreviated list of exclusion criteria:

  • Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1
  • Previous use of intraocular or periocular in the study eye within 120 days of day 1
  • Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1
  • Active proliferative diabetic retinopathy (PDR) in the study eye
  • Uncontrolled diabetes mellitus
  • Only 1 functional eye even if that eye is otherwise eligible for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
466 participants (actual)

Study arms

  • Active comparator
    Macular Laser Photocoagulation Treatment (Control)

    Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.

    Procedure: Macular Laser Photocoagulation

  • Experimental
    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4

    Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.

    Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

  • Experimental
    Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8

    Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.

    Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

    Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Time frame: Baseline and Week 52

  2. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF

    Time frame: Baseline and Week 52

  3. Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF

    Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

    Time frame: Baseline and Week 52

  4. Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF

    Time frame: Baseline and Week 52

  5. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

    Time frame: Baseline and Week 52

  6. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

    Time frame: Baseline and Week 52

07

Results

Posted Apr 20, 2015

Participant flow

Participants with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye could participate in the study.

Participant flow — Overall Study
MilestoneMacular Laser Photocoagulation Treatment (Control)Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Started156156154
Participants received treatment154155152
Completed week 52145146144
Completed week 100133125127
Completed133125127
Not completed233127
Withdrew: Adverse event544
Withdrew: Death375
Withdrew: Withdrawal by subject91111
Withdrew: Lost to follow-up245
Withdrew: Other452

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)

Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · letters correctly read
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
letters correctly readControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF).10 ± 1.0312.3 ± .7610.6 ± .69
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · ANCOVA · p = <.0001 · Mean difference (net): 12.19 · 97.5% CI 9.35 to 15.04
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · ANCOVA · p = <.0001 · Mean difference (net): 10.45 · 97.5% CI 7.73 to 13.17
SecondaryPercentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
percentage of participantsControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF3010088
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · Cochran-Mantel-Haenszel · p = .0001 · Mean difference (net): 45.9 · 97.5% CI 34.7 to 57.0
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · Cochran-Mantel-Haenszel · p = .0001 · Mean difference (net): 38.8 · 97.5% CI 27.2 to 50.3
SecondaryPercentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
percentage of participantsControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF126447
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (net): 34.2 · 97.5% CI 24.1 to 44.4
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · Cochran-Mantel-Haenszel · p = <.0001 · Mean difference (net): 23.3 · 97.5% CI 13.5 to 33.1
SecondaryPercentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF

Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF
percentage of participantsControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF225244
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · Cochran-Mantel-Haenszel · p = <.0001 · Mean difference (net): 19.7 · 97.5% CI 9.0 to 30.4
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · Cochran-Mantel-Haenszel · p = 0.0017 · Mean difference (net): 14.9 · 97.5% CI 4.4 to 25.4
SecondaryChange From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
Time frame:
Baseline and Week 52
Reported as:
Least squares mean · microns
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
micronsControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF-73.3 ± 12.09-184.1 ± 6.57-186.8 ± 6.90
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · ANCOVA · p = <.0001 · Mean difference (net): -110.8 · 97.5% CI -141.3 to -80.22
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · ANCOVA · p = <.0001 · Mean difference (net): -113.5 · 97.5% CI -144.2 to -82.75
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
scores on a scaleControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF3.7 ± 1.558.9 ± 1.588.1 ± 1.44
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · ANCOVA · p = 0.0168 · Mean difference (net): 5.19 · 97.5% CI 0.33 to 10.04
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · ANCOVA · p = 0.0323 · Mean difference (net): 4.36 · 97.5% CI -0.21 to 8.93
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
scores on a scaleControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF4.9 ± 1.447.7 ± 1.576.5 ± 1.48
Statistical analysis
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4 · ANCOVA · p = 0.1702 · Mean difference (net): 2.86 · 97.5% CI -1.82 to 7.54
  • Control vs Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8 · ANCOVA · p = 0.4067 · Mean difference (net): 1.65 · 97.5% CI -2.83 to 6.13

Adverse events

Collected over From the first study drug injection until 30 days after the last study drug injection at the latest from week 0 to week 100; From the first study drug injection until 30 days after the last study drug injection at the latest from week 0 to week 148.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control (Week 0 to Week 100)—67/154 (43.5%)91/154 (59.1%)
IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100)—67/155 (43.2%)90/155 (58.1%)
IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100)—56/152 (36.8%)76/152 (50%)
Control (Week 0 to Week 148)—84/154 (54.5%)134/154 (87%)
IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148)—85/155 (54.8%)137/155 (88.4%)
IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148)—75/152 (49.3%)136/152 (89.5%)
Most frequent serious events
Showing 10 of 340
Most frequent serious events
EventControl (Week 0 to Week 100)IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100)IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100)Control (Week 0 to Week 148)IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148)IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148)
Cardiac failure congestiveCardiac disorders5/1549/1555/1526/15411/1556/152
AnaemiaBlood and lymphatic system disorders1/1549/1555/1522/15410/1556/152
Renal failure acuteRenal and urinary disorders7/1546/1556/1529/15410/1558/152
Vitreous haemorrhageEye disorders2/1547/1552/1523/1549/1554/152
Vitreous haemorrhageEye disorders0/1540/1550/1523/1549/1554/152
CellulitisInfections and infestations4/1547/1558/1525/1549/1558/152
OsteomyelitisInfections and infestations3/1545/1552/1525/1547/1553/152
HyperkalaemiaMetabolism and nutrition disorders4/1543/1551/1526/1544/1551/152
PneumoniaInfections and infestations4/1544/1553/1524/1546/1554/152
HypoglycaemiaMetabolism and nutrition disorders1/1545/1550/1521/1546/1550/152
Most frequent other events
Showing 10 of 104
Most frequent other events
EventControl (Week 0 to Week 100)IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 100)IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 100)Control (Week 0 to Week 148)IAI;EYLEA®;BAY86-5321 2Q4 (Week 0 to Week 148)IAI;EYLEA®;BAY86-5321) 2Q8 (Week 0 to Week 148)
Conjunctival haemorrhageEye disorders53/15463/15548/15255/15463/15550/152
HypertensionVascular disorders49/15441/15542/15256/15451/15549/152
Conjunctival haemorrhageEye disorders29/15430/15527/15231/15435/15529/152
Urinary tract infectionInfections and infestations14/15417/15526/15220/15430/15532/152
Diabetic retinal oedemaEye disorders19/15422/15518/15226/15429/15523/152
Diabetes mellitusMetabolism and nutrition disorders20/15413/15519/15228/15423/15525/152
CataractEye disorders16/15421/15513/15224/15428/15521/152
AnaemiaBlood and lymphatic system disorders12/15420/15512/15215/15427/15520/152
Eye painEye disorders20/15423/15521/15223/15423/15526/152
Vitreous detachmentEye disorders15/15414/15522/15220/15420/15525/152

Baseline characteristics

Baseline population analyzed using the SAF

Age, Continuous
Age, Continuous(years)ControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Total
Mean61.7 ± 8.6562 ± 11.1663.1 ± 9.3662.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)ControlIntravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8Total
Female696873210
Male858779251
08

Study locations

51 sites
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Arcadia, California, United States
  • Beverly Hills, California, United States
  • La Jolla, California, United States
  • Mountain View, California, United States
  • Oakland, California, United States
  • Palm Desert, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Santa Barbara, California, United States
  • Torrance, California, United States
  • Colorado Springs, Colorado, United States
  • Golden, Colorado, United States
  • New London, Connecticut, United States
  • Fort Lauderdale, Florida, United States
  • Fort Myers, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Aiea, Hawaii, United States
  • Wichita, Kansas, United States
  • Portland, Maine, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Missoula, Montana, United States
  • Las Vegas, Nevada, United States
  • New Brunswick, New Jersey, United States
  • Northfield, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Lynbrook, New York, United States
  • Orchard Park, New York, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Portland, Oregon, United States
  • Kingston, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Florence, South Carolina, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Nashville, Tennessee, United States
  • Abilene, Texas, United States
  • Austin, Texas, United States
  • Harlingen, Texas, United States
  • Houston, Texas, United States
  • San Antonio (2 locations), Texas, United States
  • The Woodlands, Texas, United States
  • Salt Lake City, Utah, United States
09

References and documents

Publications

  • Dhoot DS, Moini H, Reed K, Du W, Vitti R, Berliner AJ, Singh RP. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials. Eye (Lond). 2023 Jul;37(10):2020-2025. doi: 10.1038/s41433-022-02058-7. Epub 2022 Apr 19. PubMed 35440699 ↗
  • Wykoff CC, Shah C, Dhoot D, Coleman HR, Thompson D, Du W, Baker K, Vitti R, Berliner AJ, Metzig C, Saroj N. Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study. Ophthalmology. 2019 Aug;126(8):1171-1180. doi: 10.1016/j.ophtha.2019.03.040. Epub 2019 Apr 1. PubMed 30946887 ↗
  • Midena E, Gillies M, Katz TA, Metzig C, Lu C, Ogura Y. Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. J Ophthalmol. 2018 Mar 29;2018:3640135. doi: 10.1155/2018/3640135. eCollection 2018. PubMed 29785301 ↗
  • Staurenghi G, Feltgen N, Arnold JJ, Katz TA, Metzig C, Lu C, Holz FG; VIVID-DME and VISTA-DME study investigators. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2018 Jul;102(7):954-958. doi: 10.1136/bjophthalmol-2017-310664. Epub 2017 Oct 19. PubMed 29051325 ↗
  • Wykoff CC, Marcus DM, Midena E, Korobelnik JF, Saroj N, Gibson A, Vitti R, Berliner AJ, Williams Liu Z, Zeitz O, Metzig C, Schmelter T, Heier JS. Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials. JAMA Ophthalmol. 2017 Feb 1;135(2):107-114. doi: 10.1001/jamaophthalmol.2016.4912. PubMed 28006063 ↗
  • Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous. 2016 Jul 11;2:16. doi: 10.1186/s40942-016-0041-z. eCollection 2016. PubMed 27847634 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Jan 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 2 years 3 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2011
First posted
Jun 1, 2011
Start
May 2011
Primary completionActual
Jan 2013
CompletionActual
Nov 2014
Results delay requested
Feb 11, 2014
Results first posted
Apr 20, 2015
Last update
May 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01363440
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jun 1, 2011
Start date
May 2011
Primary completion
Jan 2013
Completion
Nov 2014
Results posted
Apr 20, 2015
Last update
May 30, 2016

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion